Upregulation of the PI3K/Akt Pathway in the Tumorigenesis of Canine Thyroid Carcinoma

Journal of Veterinary Internal Medicine

Volumn 28, Issue 6, 2014, Pages 1814-1823

  Campos, M ^a   Kool, M M J ^b   Daminet, S ^a   Ducatelle, R ^a   Rutteman, G ^b   Kooistra, H S ^b   Galac, S ^b   Mol, J A ^b  

^a GHENT UNIVERSITY   (Belgium)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

C cell; Dog; Follicular; Medullary; RAS

Indexed keywords

CANIS FAMILIARIS;

ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CARCINOMA; CASE CONTROL STUDY; DOG; DOG DISEASE; GENE EXPRESSION REGULATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID TUMOR; UPREGULATION; VETERINARY;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; CARCINOMA, NEUROENDOCRINE; CASE-CONTROL STUDIES; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS; UP-REGULATION;

EID: 84911473943     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12435     Document Type: Article

References (40)

1. Loar AS. Canine thyroid tumors. In: Kirk RW, ed. Current Veterinary Therapy IX. Philadelphia, PA: WB Sauders Co; 1986:1033-1039.
2. Wucherer KL, Wilke V. Thyroid cancer in dogs: An update based on 638 cases (1995-2005). J Am Anim Hosp Assoc 2010;46:249-254.
3. Harari J, Patterson JS, Rosenthal RC. Clinical and pathologic features of thyroid tumors in 26 dogs. J Am Vet Med Assoc 1986;188:1160-1164.
4. Patnaik AK, Lieberman PH. Gross, histologic, cytochemical, and immunocytochemical study of medullary thyroid carcinoma in sixteen dogs. Vet Pathol 1991;28:223-233.
5. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13:184-199.
6. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106-3116.
7. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343.
8. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354.
9. Chen W, Bai L, Wang X, et al. Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol 2010;77:416-423.
10. Ladu S, Calvisi DF, Conner EA, et al. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008;135:1322-1332.
11. Usher SG, Radford AD, Villiers EJ, et al. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Exp Hematol 2009;37:65-77.
12. Malumbres M, Barbacid M. RAS oncogenes: The first 30 years. Nat Rev Cancer 2003;3:459-465.
13. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010;20:697-706.
14. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627.
15. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-376.
16. Salvatore D, Melillo RM, Monaco C, et al. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res 2001;61:1426-1431.
17. Cerrato A, De Falco V, Santoro M. Molecular genetics of medullary thyroid carcinoma: The quest for novel therapeutic targets. J Mol Endocrinol 2009;43:143-155.
18. Moura MM, Cavaco BM, Pinto AE, et al. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011;96:E863-E868.
19. Lee JJ, Larsson C, Lui WO, et al. A dog pedigree with familial medullary thyroid cancer. Int J Oncol 2006;29:1173-1182.
20. Kiupel M, Capen C, Miller M, et al. Histological classification of the endocrine system of domestic animals. In: Schulman FY, ed. WHO International Histological Classification of Tumors of Domestic Animals. Washington, DC: Armed Forces Institute of Pathology; 2008:25-39.
21. Campos M, Ducatelle R, Kooistra HS, et al. Immunohistochemical expression of potential therapeutic targets in canine thyroid carcinoma. J Vet Intern Med 2014;28:564-570.
22. Brinkhof B, Spee B, Rothuizen J, et al. Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem 2006;356:36-43.
23. Galac S, Kool MM, Naan EC, et al. Expression of the ACTH receptor, steroidogenic acute regulatory protein, and steroidogenic enzymes in canine cortisol-secreting adrenocortical tumors. Domest Anim Endocrinol 2010;39:259-267.
24. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-1108.
25. Vasko V, Ferrand M, Di Cristofaro J, et al. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003;88:2745-2752.
26. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-6379.
27. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
28. Minaguchi T, Yoshikawa H, Oda K, et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 2001;7:2636-2642.
29. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 2004;9:667-676.
30. Ciampi R, Mian C, Fugazzola L, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013;23:50-57.
31. Hong HH, Houle CD, Ton TV, et al. K-ras mutations in lung tumors and tumors from other organs are consistent with a common mechanism of ethylene oxide tumorigenesis in the B6C3F1 mouse. Toxicol Pathol 2007;35:81-85.
32. Scheffzek K, Ahmadian MR, Kabsch W, et al. The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997;277:333-338.
33. Richter A, Murua Escobar H, Gunther K, et al. RAS gene hot-spot mutations in canine neoplasias. J Hered 2005;96:764-765.
34. Boichard A, Croux L, Al Ghuzlan A, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 2012;97:E2031-E2035.
35. Quilliam LA, Hisaka MM, Zhong S, et al. Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors. J Biol Chem 1996;271:11076-11082.
36. Chen YT, Tan KA, Pang LY, et al. The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention. BMC Vet Res 2012;8:73.
37. London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(R)) in solid tumours. Vet Comp Oncol 2012;10:194-205.
38. Liebner DA, Shah MH. Thyroid cancer: Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab 2011;2:173-195.
39. Fuhrer D, Eszlinger M, Karger S, et al. Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours. Eur J Endocrinol 2005;152:785-790.
40. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-580.